MPI Enterprises

MPI Research was a leading global contract research organization (CRO) providing comprehensive preclinical and early clinical development services to the pharmaceutical, biotechnology, and medical device industries. The company specialized in a wide array of services including toxicology, safety pharmacology, drug metabolism and pharmacokinetics (DMPK), and bioanalytical testing. Known for its extensive expertise in both small and large molecule development, MPI Research operated one of the largest preclinical research facilities in the world. In 2018, the company was acquired by Charles River Laboratories, integrating its high-quality discovery and safety assessment capabilities into Charles River's global portfolio. Today, its legacy continues as a core component of Charles River's preclinical service offerings.